Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: attention deficit hyperactivity disorder therapies - Sosei Heptares

Drug Profile

Research programme: attention deficit hyperactivity disorder therapies - Sosei Heptares

Alternative Names: Bifemelane hydrochloride; SON-216

Latest Information Update: 13 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Sosei
  • Class Benzhydryl compounds
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 03 Dec 2018 Heptares Therapeutics has merged with Sosei to form Sosei Heptares
  • 02 Jun 2005 Preclinical trials in Attention-deficit hyperactivity disorder in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top